3 US Penny Stocks With Market Caps Under $400M To Consider

In This Article:

As the United States market experiences a late-year slump, with major indices like the Dow Jones and S&P 500 turning lower, investors are increasingly looking for opportunities outside of large-cap stocks. Penny stocks, despite their somewhat outdated name, remain an area of interest for those seeking smaller or newer companies that may offer unique value propositions. This article will explore three penny stocks that stand out due to their financial strength and potential for long-term growth in today's market landscape.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.8301

$6.25M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.19

$1.87B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$104.78M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.285

$9.2M

★★★★★★

Tantech Holdings (NasdaqCM:TANH)

$0.23

$1.59M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$3.07

$87.96M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.50

$44.07M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.39

$25.72M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.08

$96.23M

★★★★★☆

Click here to see the full list of 737 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Connect Biopharma Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for T cell-driven inflammatory diseases, with a market cap of $62.99 million.

Operations: Connect Biopharma Holdings Limited does not report any revenue segments.

Market Cap: $62.99M

Connect Biopharma Holdings Limited, with a market cap of US$62.99 million, is a pre-revenue clinical-stage biopharmaceutical firm focused on T cell-driven inflammatory diseases. Despite being unprofitable, it has reduced losses by 21.1% annually over the past five years and maintains stable short-term assets of US$115.9 million against liabilities. The company is debt-free and its stock trades at good value relative to peers. However, recent leadership changes and high volatility remain concerns for investors in penny stocks like Connect Biopharma Holdings Limited as they navigate this speculative investment landscape.

NasdaqGM:CNTB Debt to Equity History and Analysis as at Dec 2024
NasdaqGM:CNTB Debt to Equity History and Analysis as at Dec 2024

Xunlei

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Xunlei Limited, along with its subsidiaries, operates an internet platform for digital media content in the People's Republic of China and has a market cap of approximately $130.59 million.